ACADIA Pharmaceuticals Inc (ACAD)
Who owns ACADIA Pharmaceuticals Inc (ACAD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.3% of the shares are freely tradable; institutional investors hold 99.1%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 25.05 | 42,896,690 | +0.0 | 03/31/2026 |
| BlackRock Inc | 12.59 | 21,550,921 | +3.8 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 5.06 | 8,671,645 | +0.0 | 03/31/2026 |
| State Street Corp | 4.87 | 8,332,771 | +5.3 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 4.17 | 7,144,524 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.31 | 5,661,400 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 2.02 | 3,464,689 | +7.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.52 | 7,731,349 | +0.0 | 07/28/2026 |
| Vanguard Morn Total Stk Mkt Idx Investor | 2.38 | 4,075,731 | +0.5 | 06/30/2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.30 | 3,934,886 | +0.6 | 07/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 30. Jul 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 50 | 26.17 | 1,309 |
| 30. Jul 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 16,508 | 26.13 | 431,354 |
| 29. Jul 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Other | 32,272 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.